Dharwadkar Pooja, Greenan Garrett, Stoffel Elena M, Burstein Ezra, Pirzadeh-Miller Sara, Lahiri Sayoni, Mauer Caitlin, Singal Amit G, Murphy Caitlin C
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Clin Gastroenterol Hepatol. 2022 Feb;20(2):353-361.e3. doi: 10.1016/j.cgh.2020.12.025. Epub 2020 Dec 24.
BACKGROUND & AIMS: Up to 20% of younger patients (age <50 years) diagnosed with colorectal cancer (CRC) have germline mutations in cancer susceptibility genes. Germline genetic testing may guide clinical management and facilitate earlier intervention in affected relatives. Few studies have characterized differences in genetic testing by race/ethnicity.
We identified young adults (age 18-49 years) diagnosed with CRC between 2009 and 2017 in 2 health systems in Dallas, TX. We evaluated referral to genetic counseling, attendance at genetic counseling appointments, and receipt of germline genetic testing by race/ethnicity.
Of 385 patients with young-onset CRC (median age at diagnosis 44.4 years), 176 (45.7%) were Hispanic, 98 (25.4%) non-Hispanic Black, and 111 (28.8%) non-Hispanic White. Most patients (76.9%) received immunohistochemistry (IHC) for mismatch repair proteins, and there was no difference in receipt of IHC by race/ethnicity. However, a lower proportion of Black patients were referred to genetic counseling (50.0% vs White patients 54.1% vs Hispanic patients 65.9%; P = .02) and attended genetic counseling appointments (61.2% vs 81.7% White patients vs 86.2% Hispanic patients; P < .01). Of 141 patients receiving genetic testing, 38 (27.0%) had a pathogenic or likely pathogenic variant in a cancer susceptibility gene. An additional 33 patients (23.4%) had variants of uncertain significance, of which 84.8% occurred in racial/ethnic minorities.
In a diverse population of patients diagnosed with young-onset CRC, we observed racial/ethnic differences in referral to and receipt of germline genetic testing. Our findings underscore the importance of universal genetic testing to address racial/ethnic disparities in young-onset CRC.
在诊断为结直肠癌(CRC)的年轻患者(年龄<50岁)中,高达20%的患者在癌症易感基因中存在种系突变。种系基因检测可指导临床管理,并有助于对受影响的亲属进行早期干预。很少有研究描述种族/族裔在基因检测方面的差异。
我们在德克萨斯州达拉斯市的2个医疗系统中,确定了2009年至2017年间诊断为CRC的年轻成年人(年龄18 - 49岁)。我们评估了按种族/族裔划分的基因咨询转诊情况、基因咨询预约的就诊情况以及种系基因检测的接受情况。
在385例年轻发病的CRC患者中(诊断时的中位年龄为44.4岁),176例(45.7%)为西班牙裔,98例(25.4%)为非西班牙裔黑人,111例(28.8%)为非西班牙裔白人。大多数患者(76.9%)接受了错配修复蛋白的免疫组织化学(IHC)检测,种族/族裔在接受IHC检测方面没有差异。然而,转诊至基因咨询的黑人患者比例较低(50.0%,白人患者为54.1%,西班牙裔患者为65.9%;P = 0.02),且参加基因咨询预约的比例也较低(61.2%,白人患者为81.7%,西班牙裔患者为86.2%;P < 0.01)。在141例接受基因检测的患者中,有38例(27.0%)在癌症易感基因中存在致病或可能致病的变异。另外33例患者(23.4%)存在意义不确定的变异,其中84.8%发生在少数种族/族裔中。
在诊断为年轻发病CRC的不同人群中,我们观察到种系基因检测的转诊和接受情况存在种族/族裔差异。我们的研究结果强调了进行普遍基因检测以解决年轻发病CRC中的种族/族裔差异的重要性。